Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2010 | Research

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy

Authors: Ondrej Slaby, Jana Jancovicova, Radek Lakomy, Marek Svoboda, Alexandr Poprach, Pavel Fabian, Leos Kren, Jaroslav Michalek, Rostislav Vyzula

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Abstract

Background

MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies have shown altered expression levels of several microRNAs in renal cell carcinoma.

Methods

We examined the expression levels of selected microRNAs in 38 samples of conventional renal cell carcinoma (RCC) and 10 samples of non-tumoral renal parenchyma using TaqMan real-time PCR method.

Results

The expression levels of miRNA-155 (p < 0.0001), miRNA-210 (p < 0.0001), miRNA-106a (p < 0.0001) and miRNA-106b (p < 0.0001) were significantly over-expressed in tumor tissue, whereas the expression of miRNA-141 (p < 0.0001) and miRNA-200c (p < 0.0001) were significantly decreased in RCC samples. There were no significant differences between expression levels of miRNA-182 and miRNA-200b in tumor samples and renal parenchyma. Our data suggest that expression levels of miRNA-106b are significantly lower in tumors of patients who developed metastasis (p = 0.030) and miR-106b is a potential predictive marker of early metastasis after nephrectomy in RCC patients (long-rank p = 0.032).

Conclusions

We have confirmed previous observations obtained by miRNA microarray analysis using standardized real-time PCR method. For the first time, we have identified a prognostic significance of miRNA-106b, which, after validation on a larger group of patients, maybe useful as a promising biomarker in patients with RCC.

Available only for authorised users

Richie JP, Jonasch E, Kantoff PW: Renal Cell Carcinoma. Holland-Frei Cancer Medicine. Edited by: Kufe WD, Bast RC, Hait WN, et al. 2006, Hamilton (Canada), BC Decker, 1401-1410. 7 edn

Bukowski RM: Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer. 2009, 115: 2273-2281. 10.1002/cncr.24226.CrossRef

Yan BC, Mackinnon AC, Al-Ahmadie HA: Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. Arch Pathol Lab Med. 2009, 133: 102610-32.

Inui M, Martello G, Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010, 11 (4): 252-263.CrossRef

Galasso M, Elena Sana M, Volinia S: Non-coding RNAs: a key to future personalized molecular therapy?. Genome Med. 2010, 18 (2(2)): 12-10.1186/gm133.CrossRef

Brown BD, Naldini L: Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet. 2009, 10: 578-585. 10.1038/nrg2628.CrossRef

Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009, 55: 623-631. 10.1373/clinchem.2008.112805.CrossRef

Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840.CrossRef

Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med. 2009, 60: 167-179. 10.1146/annurev.med.59.053006.104707.CrossRef

10.

Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM: MicroRNA expression and function in cancer. Trends Mol Med. 2006, 12: 580-587. 10.1016/j.molmed.2006.10.006.CrossRef

11.

Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009, 8: 102-10.1186/1476-4598-8-102.CrossRef

12.

Slaby O, Svoboda M, Michalek J, Vyzula R: DNA and microRNA microarray technologies in diagnostics and prediction for patients with renal cell carcinoma. Klin Onkol. 2009, 22 (5): 202-209.

13.

Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol. 2009, 35 (1): 109-114. 10.3892/ijo_00000318.CrossRef

14.

Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS: Identification of a microRNA panel for clear-cell kidney cancer. Urology. 2010, 75 (4): 835-841. 10.1016/j.urology.2009.10.033.CrossRef

15.

Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008, 216 (4): 418-427. 10.1002/path.2437.CrossRef

16.

Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, Kristiansen G: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009, 13 (9B): 3918-3928. 10.1111/j.1582-4934.2009.00705.x.CrossRef

17.

Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007, 25 (5): 387-392.CrossRef

18.

Yi Z, Fu Y, Zhao S, Zhang X, Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 2010, 136 (6): 855-862. 10.1007/s00432-009-0726-x.CrossRef

19.

Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM: Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 2010, 43 (1-2): 150-158. 10.1016/j.clinbiochem.2009.07.020.CrossRef

20.

Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 2009, 35 (10): 1119-1123.CrossRef

21.

Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM: The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol. 2010, 183 (2): 743-751. 10.1016/j.juro.2009.09.086.CrossRef

22.

Faraoni I, Antonetti FR, Cardone J, Bonmassar E: miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009, 1792 (6): 497-505.CrossRef

23.

Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009, 23 (18): 2140-2151. 10.1101/gad.1820209.CrossRef

24.

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9: 582-589. 10.1038/embor.2008.74.CrossRef

25.

Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010, 11 (1): 50-54. 10.1111/j.1751-2980.2009.00413.x.CrossRef

26.

Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009, 24 (4): 652-657. 10.1111/j.1440-1746.2008.05666.x.CrossRef

27.

Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM: Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009, 100 (7): 1234-1242. 10.1111/j.1349-7006.2009.01164.x.CrossRef

28.

Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O'Sullivan B, Waldron J, Gullane P, Cummings B, Liu FF: Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res. 2010, 16 (4): 1129-1139. 10.1158/1078-0432.CCR-09-2166.CrossRef

29.

Petrocca F, Vecchione A, Croce CM: Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008, 68 (20): 8191-8194. 10.1158/0008-5472.CAN-08-1768.CrossRef

30.

Bierie B, Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006, 6 (7): 506-520. 10.1038/nrc1926.CrossRef

31.

Joshi A, Cao D: TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci. 2010, 15: 180-194. 10.2741/3614.CrossRef

Title: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
Authors: Ondrej Slaby
Jana Jancovicova
Radek Lakomy
Marek Svoboda
Alexandr Poprach
Pavel Fabian
Leos Kren
Jaroslav Michalek
Rostislav Vyzula
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-29-90

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: Phase I trial

Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods

8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker of oxidative damage in oesophageal cancer patients: lack of association with antioxidant vitamins and polymorphism of hOGG1 and GST

Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines

Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer